Your Feed

Filter by
See content from
Back to the latest
Thumbnail for Treating High Risk Multiple Myeloma an Evidence-Based Approach | Katja Weisel, MD | IMS 2024
Playlist: IMS 2024

Treating High Risk Multiple Myeloma an Evidence-Based Approach | Katja Weisel, MD | IMS 2024

Video details & playlist
Thumbnail for New IMS High Risk Multiple Myeloma Consensus Definition | Jill Corre, PharmD, PhD | IMS 2024
Playlist: IMS 2024

New IMS High Risk Multiple Myeloma Consensus Definition | Jill Corre, PharmD, PhD | IMS 2024

Video details & playlist
Thumbnail for New Criteria for Defining High Risk Multiple Myeloma | Gareth Morgan & Faith Davies | IMS 2024
Playlist: IMS 2024

New Criteria for Defining High Risk Multiple Myeloma | Gareth Morgan & Faith Davies | IMS 2024

Video details & playlist
Thumbnail for Investigating Oral Toxicity Associated with Talquetamab in Myeloma | Rakesh Popat | IMS 2024
Playlist: IMS 2024

Investigating Oral Toxicity Associated with Talquetamab in Myeloma | Rakesh Popat | IMS 2024

Video details & playlist
Thumbnail for Thematic Analysis on Talquetamab and Patient Perceptions | Alexandra L. Greenwood, BSc | IMS 2024
Playlist: IMS 2024

Thematic Analysis on Talquetamab and Patient Perceptions | Alexandra L. Greenwood, BSc | IMS 2024

Video details & playlist
Avatar
Isaac
Multiple Myeloma Discussion • October 2, 2024
Experiencing Bitter Taste After SCT?
AI-generated title
Hello, I had autologous stem cell transplant on 5 SEP 2025. since then I've had this bitter taste in my mouth that makes certain foods such as steaks, very unpleasant to me. Even when I'm not eating, I can taste a little bit of the bitterness in the back of my mouth. Has anyone else experienced this after a SCT? If so, how long did you continue to experience this before it went away? Thank you
Avatar
llogue82
Multiple Myeloma Discussion • October 1, 2024
Revlimid Neuropathy & Pomalyst Experiences?
AI-generated title
I am having difficulty with Revlimid as it is causing increase’s neuropathy. Dr I talking about dose reduction to 10 mg 14 days on and 14 days of or switching to Polymast? Any one have experience with Polymast? I may be spelling this wrong
Avatar
Iliana • Admin
Multiple Myeloma Discussion • October 1, 2024
New Patient Guide to Bispecific Antibodies
AI-generated title
🚨 New Resource Alert 🚨 Discover the future of multiple myeloma treatment with our Bispecific Antibody Guide! Developed by HealthTree alongside myeloma patients and caregivers, and reviewed by medical experts, this multimedia guide dives deep into the world of bispecific antibodies, a groundbreaking immunotherapy. 💡 Whether you're just learning about bispecifics or need more details, this guide is packed with valuable insights for myeloma patients.🌟 💪 Empower yourself with the knowledge to make informed decisions! Start your learning here: Myeloma Bispecific Antibody Guide https://healthtree.org/myeloma/guides/bispecific-antibodies/introduction?utm_source=&utm_medium=connect&utm_campaign=bispecificguide&utm_content=all+myeloma
HealthTree

HealthTree

https://healthtree.org/myeloma/guides/bispecific-antibodies/introduction?utm_source=&utm_medium=connect&utm_campaign=bispecificguide&utm_content=all+myeloma
Avatar
Iliana • Admin
Multiple Myeloma Discussion • September 30, 2024
New Trial Opportunity for Relapsed Myeloma
AI-generated title
A phase III study by Bristol Myers Squibb is open comparing a new oral drug called mezigdomide (CC-92480), bortezomib and dexamethasone vs. pomalidomide, bortezomib and dexamethasone. Mezigdomide is part of a new class of drugs called CELMoDs. Study participants who have relapsed or refractory myeloma, prior exposure to lenalidomide and at least 1-3 lines of therapy are welcome to join. Learn more about this study here: https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT05519085?cid=s_2839272
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | BMS Clinical Trials

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | BMS Clinical Trials

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT05519085?cid=s_2839272
Avatar
Iliana • Admin
Multiple Myeloma Discussion • September 30, 2024
Trial Opportunity for Relapsed Myeloma
AI-generated title
People with multiple myeloma which has come back or stopped responding to treatment may be able to join the MagnetisMM-32 trial. Together, we could make a difference.     For more details about Pfizer’s MagnetisMM-32 clinical trial, please visit: https://www.pfizerclinicaltrials.com/nct06152575-multiple-myeloma-trial?cmp=789d7f1a-53cf-4154-bafc-ad212d49eef7&ttype=FB
Pfizer Clinical Trials | Official Participant Site

Pfizer Clinical Trials | Official Participant Site

Join us in the pursuit to change patients’ lives. Each and every person in a clinical trial plays a powerful role.

https://www.pfizerclinicaltrials.com/nct06152575-multiple-myeloma-trial?cmp=789d7f1a-53cf-4154-bafc-ad212d49eef7&ttype=FB